ONCS

About ONCS

OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its technology platform, ImmunoPulse, is a drug-device therapeutic modality comprised of intertumoral EP delivery devices, such as the OncoSec Medical System (OMS) EP device. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The OMS EP device adapts to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. Its product candidate, TAVO is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid (TAVO) with plasmid DNA-encoded, IL-12, and is delivered into a tumor using its electroporation device.